Under the model, drugmakers supply hepatitis C treatments in return for subscription-based payments. The state would pay a fixed dollar amount for unlimited access to the medication for five years. The program would only apply to state Medicaid beneficiaries or incarcerated patients.
The pricing model aims to limit the amount the state pays for hepatitis C treatments, while also treating more individuals. The Louisiana Health Department hopes to treat more than 10,000 people by the end of 2020 and keep the total spending on hepatitis C drugs to $35 million or less, the collective amount Medicaid and the Louisiana Department of Corrections spent in fiscal year 2018.
“This subscription model effectively caps the state’s spending on expensive hepatitis C drugs and creates an incentive to treat as many infected people as possible. For the drug manufacturer, this model would guarantee fixed revenue for a contracted period of time and allow the drug manufacturer to expand their product reach into populations that otherwise would not have received treatment,” Louisiana Gov. John Bel Edwards told STAT.
The state has been looking into a subscription payment model, among other proposals, for more than a year to help eliminate hepatitis C in the state without spending more on the cost of the medications.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.